{
    "clinical_study": {
        "@rank": "121187", 
        "acronym": "LT", 
        "arm_group": {
            "arm_group_label": "Hepabig", 
            "description": "Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation"
        }, 
        "biospec_descr": {
            "textblock": "serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V.\n      Hepabig injection used for prevention of hepatitis B relapse after liver transplantation."
        }, 
        "brief_title": "Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Liver Cirrhosis", 
            "Chronic Hepatitis B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u226418 years old\n\n          -  Patients who understand the informed consent form and signed the form voluntarily\n\n          -  Patients who underwent liver transplantation due to HBV related disease and will be\n             treated for prevention of hepatitis B relapse after liver transplantation\n\n        Exclusion Criteria:\n\n          -  Multi-organ recipient or reimplantation\n\n          -  IgA Deficiency\n\n          -  Serious nephropathy\n\n          -  Serious cardiovascular system failure within 6 months\n\n          -  Ischemic or hemolytic anemia\n\n          -  Condition of immunosuppression and immunodeficiency\n\n          -  Hypersensitivity or allergic to blood products\n\n          -  HIV or HCV positive\n\n          -  Participation to other clinical trial within 3 months\n\n          -  Pregnancy or breast feeding\n\n          -  Those who the investigator determines inappropriate to participate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Those who receiving I.V. Hepabig injection for prevention of hepatitis B relapse after\n        liver transplantation"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125071", 
            "org_study_id": "I.V. Hepabig injection_IIT"
        }, 
        "intervention": {
            "arm_group_label": "Hepabig", 
            "description": "Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.", 
            "intervention_name": "Blood Sample Collection", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "contact": {
                "email": "kimdg@catholic.ac.kr", 
                "last_name": "Dong Gu Kim, MD, PhD", 
                "phone": "02-2128-1158"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "137-701"
                }, 
                "name": "The Catholic University, Seoul St Mary Hospital"
            }, 
            "investigator": {
                "last_name": "Dong Gu Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Exploratory Clinical Trial to Evaluate the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation", 
        "overall_contact": {
            "email": "kimdg@catholic.ac.kr", 
            "last_name": "Dong Gu Kim, MD, PhD", 
            "phone": "+82-2258-1158"
        }, 
        "overall_contact_backup": {
            "email": "waystolove@catholic.ac.kr", 
            "last_name": "Seung Hoon Han, MD", 
            "phone": "+82-2-2258-7884"
        }, 
        "overall_official": {
            "affiliation": "The Catholic University, Seoul St Mary Hospital", 
            "last_name": "Dong Gu Kim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The anti-HBs titer is measured on the day of LT, day 1, week 1, week 4, week 12 and week 24, to determine the pharmacokinetic characteristic of Hepabig I.V. injection", 
            "measure": "anti-HBs titer", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125071"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul St. Mary's Hospital", 
            "investigator_full_name": "Dong-Gu Kim", 
            "investigator_title": "MD, Phd", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Seoul St. Mary's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Seoul St. Mary's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}